Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Perioperative apatinib plus toripalimab with chemotherapy in resectable non-small cell lung cancer
ChiCTR2500109994Phase 2Not yet recruiting
- Sponsor
- Peking Union Medical College Hospital
- Start
- Sep 2025
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Rivoceranib and toripalimab in non-small cell lung cancer (NSCLC), sponsored by Peking Union Medical College Hospital. Primary endpoint: Major Pathologic Response (MPR). Planned start Sep 2025; status: not yet recruiting.
02
Drugs
Rivoceranibtoripalimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2500109994.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500109994.